Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk

Graphical Abstract

Highlights
- Obesity results in a profound perturbation of the plasma metabolome
- At any given BMI, abnormal metabolomes associate with different health outcomes
- At any given BMI, different genetic obesity risks do not change the metabolome
- A metabolome signature effectively tracks changes in obesity

Authors
Elizabeth T. Cirulli, Lining Guo, Christine Leon Swisher, ..., Bernard Thorens, J. Craig Venter, Amalio Telenti

Correspondence
liz.cirulli@gmail.com (E.T.C.), atelenti@scripps.edu (A.T.)

In Brief
Obesity is a heterogeneous and complex disease that is imprecisely measured by BMI. Cirulli et al. used non-targeted metabolomics and whole-genome sequencing to identify metabolic and genetic signatures of obesity and find that the metabolome captures clinically relevant phenotypes of obesity and is a better health predictor than genetic risk.
Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk

Elizabeth T. Cirulli,1,6,* Lining Guo,2 Christine Leon Swisher,1 Naisha Shah,1 Lei Huang,1 Lori A. Napier,1 Ewen F. Kirkness,1 Tim D. Spector,3 C. Thomas Caskey,4 Bernard Thorens,5 J. Craig Venter,6 and Amalio Telenti7,8

1Human Longevity, Inc., San Diego, CA 92121, USA
2Metabolon, Inc., Durham, NC, USA
3Department of Twin Research and Genetic Epidemiology, King’s College London, London, UK
4Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
5Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
6J. Craig Venter Institute, La Jolla, CA 92037, USA
7The Scripps Research Institute, La Jolla, CA 92037, USA
8Lead Contact
*Correspondence: liz.cirulli@gmail.com (E.T.C.), atelenti@scripps.edu (A.T.)

https://doi.org/10.1016/j.cmet.2018.09.022

SUMMARY

Obesity is a heterogeneous phenotype that is crudely measured by body mass index (BMI). There is a need for a more precise yet portable method of phenotyping and categorizing risk in large numbers of people with obesity to advance clinical care and drug development. Here, we used non-targeted metabolomics and whole-genome sequencing to identify metabolic and genetic signatures of obesity. We find that obesity results in profound perturbation of the metabolome; nearly a third of the assayed metabolites associated with changes in BMI. A metabolome signature identifies the healthy obese and lean individuals with abnormal metabolomes—these groups differ in health outcomes and underlying genetic risk. Specifically, an abnormal metabolome associated with a 2- to 5-fold increase in cardiovascular events when comparing individuals who were matched for BMI but had opposing metabolome signatures. Because metabolome profiling identifies clinically meaningful heterogeneity in obesity, this approach could help select patients for clinical trials.

INTRODUCTION

Obesity is one of the most widespread problems facing our society’s health today. Excessive weight significantly increases risk for conditions like diabetes mellitus and cardiovascular disease (Hales et al., 2017; Whitlock et al., 2009). Worldwide, the prevalence of obesity has nearly tripled since 1975, with 39% of the world’s adults being overweight and 13% being obese (WHO, 2018). The high prevalence can partially be attributed to increasing consumption of hypercaloric foods and sedentary lifestyles (WHO, 2018). Previous studies have identified metabolic signatures associated with obesity, including increased levels of branched-chain and aromatic amino acids as well as glycerol and glycerophosphocholines (Butte et al., 2015; Chen et al., 2015; Ho et al., 2016; Menni et al., 2017; Park et al., 2015; Piening et al., 2018). However, prior work has been limited by focusing on a relatively small numbers of metabolites, individuals, or obesity phenotypes.

The characterization of the metabolites that are associated with obesity can provide insights into the mechanisms that lead to this disease and associated consequences. Longitudinal assessment of weight gain and weight loss over time may indicate whether there are metabolic changes that cause obesity—meaning that current metabolite levels could predict future weight changes—or whether all metabolite changes associated with obesity are a consequence of weight changes. Drawing genetics into this assessment allows the determination of whether genetic variation leads to metabolic changes that subsequently result in obesity, allowing the further delineation of the causal pathway to obesity. Finally, research in this area may identify biomarkers of obesity and of different types of obesity, for example biomarkers of so-called healthy obesity (Neeland et al., 2018).

There are recent calls to improve phenotyping in very large numbers of obese people with the goals of understanding factors that make people susceptible to (or protected from) obesity, accompanied by a better elucidation of the factors that account for variability in success of different obesity treatments (Yanovski and Yanovski, 2018). Here, in an effort to understand the relationship between metabolic perturbations and the obese state, we analyzed 2,396 individuals with longitudinal measurements of body mass index (BMI), anthropomorphic data, whole-body DEXA scans, and metabolome, combined with baseline genetic risk. The metabolome assay covered up to 1,007 metabolites at up to three distinct time points for each individual over the course of study. We identified associations between nearly a third of the metabolome and BMI, and we show that metabolite levels can predict obesity status with ~80%–90% specificity and sensitivity. The metabolome profile is a strong indicator of metabolic health compared to the polygenic risk assessment and anthropomorphic measurements of BMI.
RESULTS

Profound Perturbation of Metabolome by Obesity
Metabolites Associated with BMI

We compared the levels of individual metabolites to the BMIs of 832, 882, and 861 unrelated individuals of European ancestry in the TwinsUK cohort (Moayyeri et al., 2013) at three time points spanning a total range of 8–18 years. We identified 284 metabolites that were significantly associated ($p < 5.5 \times 10^{-6}$) with BMI at one or more time points (Table S1). We focused on 110 metabolites that were significantly associated with BMI at all 3 time points and sought to replicate the associations in an independent sample of 427 unrelated individuals of European ancestry participating in the Health Nucleus cohort (Perkins et al., 2017). In total, our analyses identified 307 metabolites that were significantly associated with BMI in at least one cohort and time point (Table S1). We identified 83 metabolites that showed directions of effect that were consistent between the two cohorts, of which 49 were statistically significant replications (Figure 1; Table 1). The most significantly associated metabolite was urate (uric acid; $p$ value $1.2 \times 10^{-3}$ for combined analysis of TwinsUK time point 1 and Health Nucleus data).

Patterns in Metabolite Change According to BMI

The majority of the 49 BMI-associated metabolites increased with increasing BMI ($n = 35$) (Figure 1; Table S1). This included glucose and, notably, mannose, which has recently been highlighted as playing a role in insulin resistance (Lee et al., 2016). Most metabolites change linearly (both proportionally and inversely) with BMI (Figure 1C). Branched-chain and aromatic amino acids as well as metabolites related to nucleotide metabolism like urate had the most rapid increases. Those that decreased ($n = 14$) included phospholipids and lysolipids, as well as the amino acids asparagine and N-acetylglycine and the xenobiotic cinnamoylglycine, which has been identified as a product of the microbiome (Wikoff et al., 2009). The negatively associated lipids tended to reflect HDL (high-density lipoprotein) levels, while the positively correlated lipids were more representative of triglyceride levels (Tables 1 and S1). Of particular interest was the association between BMI and cortisone, a metabolite of the steroid hormone cortisol. We identified lower levels among the obese individuals, which is consistent with previous reports (Björntorp and Rosmond, 2000; Praveen et al., 2011; Walker et al., 2000; Wirix et al., 2017). We examined the overall composition of the distributions of these metabolites via
| Super Pathway | Metabolite | Subpathway (Correlated Blood Lipids) | Direction of Effect (Rank) | BMI $r^2$ |
|---------------|------------|--------------------------------------|---------------------------|-----------|
| Nucleotide    | urate      | Pur.Met.                             | ↑ (1)                     | 16.4%     |
|               | N2,N2-dimethylguanosine | Pur.Met.                             | ↑ (6)                     | 8.8%      |
|               | N6-carbamoylthreonyladenosine | Pur.Met.                             | ↑ (28)                    | 7.3%      |
| Amino acid    | glutamate  | Glu.Met.                             | ↑ (2)                     | 11.5%     |
|               | N-acetylglycine | Gly.Met.                             | ↓ (9)                     | 9.0%      |
|               | 5-methylthioadenosine (MTA) | Poly.Met.                            | ↑ (10)                    | 7.5%      |
|               | valine     | Leu.Met.                             | ↑ (11)                    | 8.8%      |
|               | aspartate  | Ala.Met.                             | ↑ (16)                    | 7.0%      |
|               | N-acetylvaline | Leu.Met.                             | ↑ (18)                    | 7.3%      |
|               | kynurenate | Try.Met.                             | ↑ (19)                    | 6.0%      |
|               | alanine    | Ala.Met.                             | ↑ (23)                    | 5.3%      |
|               | asparagine | Ala.Met.                             | ↓ (26)                    | 3.7%      |
|               | tyrosine   | Phe.Met.                             | ↑ (34)                    | 1.8%      |
|               | leucine    | Leu.Met.                             | ↑ (37)                    | 6.8%      |
|               | N-acetyltirosine | Phe.Met.                             | ↑ (40)                    | 4.2%      |
|               | 2-methylbutyrylcarnitine (C5) | Leu.Met.                             | ↑ (41)                    | 8.3%      |
| Lipid         | 1-(1-ethyl-palmitoyl)-2-oleoyl-GPC | Plas. (HDL, TG)                     | ↓ (3)                     | 7.1%      |
|               | 1-stearoyl-2-dihomo-linolenoyl-GPC | Phos.Met. (TG, Chol)                | ↑ (4)                     | 9.8%      |
|               | 1-eicosenoyl-GPC | Lysolipid                           | ↓ (5)                     | 6.2%      |
|               | 1-arachidoyl-GPC | Lysolipid                           | ↓ (7)                     | 8.6%      |
|               | 1-(1-ethyl-stearoyl)-2-oleoyl-GPC | Phos.lip. (HDL)                     | ↓ (8)                     | 6.5%      |
|               | propionylcarnitine | BCAA.Met                             | ↑ (12)                    | 9.9%      |
|               | 1-nonadecanoyl-GPC | Lysolipid                           | ↓ (14)                    | 4.2%      |
|               | 1-linoleoyl-GPC | Lysolipid                           | ↓ (15)                    | 4.9%      |
|               | sphingomyelin | Sph.Met. (Chol)                     | ↑ (20)                    | 6.8%      |
|               | 1-palmitoyl-2-dihomo-linolenoyl-GPC | Phos.Met. (TG, Chol)                | ↑ (21)                    | 5.1%      |
|               | 1-(1-ethyl-palmitoyl)-2-linoleoyl-GPC | Phos.Met. (HDL)                     | ↓ (22)                    | 5.7%      |
|               | 1-palmitoyl-3-linoleoyl-glycerol | Phos.Met. (TG)                      | ↑ (24)                    | 7.6%      |
|               | 1-oleoyl-2-linoleoyl-GPC | Phos.Met.                           | ↓ (27)                    | 5.6%      |
|               | 1-(1-ethyl-stearoyl)-2-docosahexaenoyl-GPC | Phos.Met.                        | ↓ (29)                    | 2.5%      |
|               | 1-oleoyl-3-linoleoyl-glycerol | Di.gly. (TG, HDL)                  | ↑ (30)                    | 6.3%      |
|               | carnitine  | Car.Met.                             | ↑ (33)                    | 7.5%      |
|               | 1-palmitoyl-2-linoleoyl-glycerol | Phos.Met. (TG, HDL)                | ↑ (36)                    | 7.2%      |
|               | 1-oleoyl-2-linoleoyl-glycerol | Di.gly. (TG, HDL)                  | ↑ (38)                    | 5.9%      |
|               | 1,2-dilinoleoyl-GPC | Phos.Met.                           | ↓ (39)                    | 4.2%      |
|               | 1-palmitoleoyl-2-oleoyl-glycerol | Phos.lip. (TG)                     | ↑ (42)                    | 5.6%      |
|               | 1-palmitoleoyl-3-oleoyl-glycerol | Phos.lip. (TG)                     | ↑ (45)                    | 6.0%      |
|               | 1-palmitoyl-2-adrenoyl-GPC | Phos.Met. (TG)                      | ↑ (47)                    | 2.9%      |
|               | cortisone  | Plas. (HDL, TG)                      | ↓ (49)                    | 2.5%      |
| Energy        | succinylcarnitine | TCA                                  | ↑ (13)                    | 9.8%      |
| Carbohydrate  | mannose    | Fru.Met.                             | ↑ (17)                    | 6.6%      |
|               | glucose    | Pyr.Met.                             | ↑ (48)                    | 6.3%      |
| Xenobiotics   | cinnamoylglycine | Food                                | ↓ (43)                    | 3.5%      |
| Cofactors/ vitamins | gulonic acid | Asc.Met.                             | ↑ (46)                    | 3.2%      |
|               | quinolinate | Nic.Met.                             | ↑ (44)                    | 8.4%      |

(Continued on next page)
principal component analysis and found complex underlying correlations; in particular, the first principal component explained ~20% of the total variation in the levels of these 49 metabolites. We additionally examined each of the 49 metabolites in just those of normal weight, overweight, or obese separately, and we found directions of effect that were largely consistent with those seen in the group as a whole (Table S1).

**Modeling the Metabolome of Obesity**

We used ridge regression to build a model that would predict BMI from the 49 BMI-associated metabolites (Figure 2). We chose this method to focus on the most stringently associated metabolites and to remove effects of collinearity, and we found similar results when using lasso regression. We combined our data for the first visit of the TwinsUK cohort and the Health Nucleus cohort and trained with 10-fold cross-validation on a random half of the population. In our test set of the other half of the data, we found that the model could explain 39.1% of the variation in BMI (Figure 2A). In predicting whether participants were obese (BMI ≥ 30) or normal weight (BMI 18.5–25), the model had an area under the curve (AUC) of 0.922, specificity of 89.1%, and sensitivity of 80.2% (Figure S1). The model based on the metabolite signature was thereafter used as a tool to define mBMI, the predicted BMI on the basis of metabolite are indicated in parentheses.

| Super Pathway | Metabolite | Subpathway (Correlated Blood Lipids) | Direction of Effect | BMI $r^2$ |
|---------------|------------|--------------------------------------|---------------------|-----------|
| Peptide       | N-acetylcarnosine | DiDep. | 1 (25) | 6.9% |
|               | gamma-glutamylphenylalanine | Gam. | 1 (32) | 6.0% |
|               | gamma-glutamyltyrosine | Gam. | 1 (35) | 4.6% |

Subpathway acronyms: Ala.Met., alanine and aspartate metabolism; Asc.Met., ascorbate and aldarate metabolism; BCAA.Met, branched-chain amino acid metabolism; Car.Met., carnitine metabolism; Di.gly., diacylglycerol; DiDep., dipeptide derivative; Food, food component/plant; Fru.Met., fructose, mannose, and galactose metabolism; Gam., gamma-glutamyl amino acid; Glu.Met., glutamate metabolism; Gly.Met., glycine, serine, and threonine metabolism; Lau.Met., leucine, isoleucine, and valine metabolism; Lysolipid, lysolipid; Nic.Met., nicotinate and nicotinamide metabolism; Phe.Met., phenylalanine and tyrosine metabolism; Phos.lip., phospholipid; Phos.Met., phospholipid metabolism; Plas., plasmalogens; Poly.Met., polyamine metabolism; Pur.Met., purine metabolism; Pyr.Met., glycolysis, gluconeogenesis, and pyruvate metabolism; Sph.Met., sphingolipid metabolism; Steroid, steroid; TCA, TCA cycle; Try.Met., tryptophan metabolism.

Rank indicates order of significance of association with BMI.

Mean $r^2$ indicates the percent variation in BMI explained by each metabolite in univariate analysis for a combined analysis of the first time point of the TwinsUK cohort and the Health Nucleus data.

Blood labs for TG (triglycerides), Chol (cholesterol), HDL (high-density lipoprotein), or LDL (low-density lipoprotein) that had an $r^2 > 0.1$ with the metabolite.

**Identification and Characterization of Metabolic BMI Outliers**

Having established a model to predict BMI using the metabolome (mBMI), we split the participants into five groups (Figure 2A). Three groups included individuals whose metabolome accurately predicted their BMI, as defined by having a residual between −0.5 and 0.5 from a regression analysis of mBMI with age, sex, and BMI included as predictors. These criteria delineated ~80% of individuals as having an mBMI relatively concordant with actual BMI. They were characterized as having a normal BMI (18.5–25), overweight (25–30), or obese (>30). Two groups were characterized as outliers: these included individuals whose metabolome predicted a substantially lower mBMI than the actual BMI (mBMI < BMI, residual < −0.5) or a substantially higher mBMI than the actual BMI (mBMI > BMI, residual > 0.5). While these two outlier groups had the same weight and age distribution (Figure 2B), they had very different values for many of the phenotypes of metabolic health collected from these cohorts (Figures 2B and 2C). Individuals with an mBMI prediction that was substantially lower than their actual BMI had levels of insulin resistance, total triglycerides, HDL, blood pressure, waist/hip ratio, android/gynoid ratio, percent body fat, percent visceral fat, and percent subcutaneous fat that were similar to normal-weight individuals with healthy metabolomes. Individuals with an mBMI prediction that was substantially higher than their actual BMI had levels of these traits that were similar to those of obese individuals with obese metabolomes. Evaluating these data from a more clinical perspective, with individuals separated into clinical categories such as normal BMI with obese metabolome and obese BMI with healthy metabolome, generally confirmed these effects (Figures 3 and S2). Our findings suggest that the metabolome can be used as a clinically meaningful instrument, where obesity is analyzed in the context of its metabolome perturbation rather than just on BMI alone. Thus, our results are important in the frame of the current debate on the metabolically “healthy” obese and also for the identification of individuals with normal BMI (Chen et al., 2015) but poor metabolic health (Caleyachetty et al., 2017; Iglesias Molli et al., 2017).
Having characterized these outliers, we revisited their metabolome differences. As the 49 metabolites were chosen for their association with BMI, there is no a priori expectation that they would all show differences between the group with mBMI >> BMI and the group with mBMI << BMI, as these two groups have the same BMI distribution. However, we found that these two outlier groups did indeed have statistically significant differences in their metabolite levels for all of the 49 metabolites but two: asparagine and cortisone (Figure S3). This lack of association of cortisone with mBMI/BMI outliers shows that its correlation with BMI does not appear to extend to metabolic health, which presents interesting questions about the underlying biology. Although cortisone’s parent compound cortisol has been reported as associated with obesity, there are inconsistent relationships between cortisol and metabolic parameters in the literature (Abraham et al., 2013; Incollingo Rodriguez et al., 2015). It is also known that cortisol levels change throughout the day, and this factor could have influenced our results as the participants were not all measured at the same time. We additionally investigated the association between each of the BMI-associated metabolites and insulin resistance, as many previously reported markers of obesity have also been markers of diabetes (Ho et al., 2016; Park et al., 2015). We had quantitative insulin resistance measurements for 515 unrelated, European-ancestry participants. After controlling for BMI, we found that 12 of the 49 BMI-associated metabolites were also significantly associated (correcting for 49 tests requires $p < 0.001$) with insulin resistance, all with positive directions of effect: tyrosine, alanine, kynurenate, gamma-glutamyltyrosine, 1-oleoyl-3-linoleoyl-glycerol (18:1/18:2), six phospholipids, and, as expected, glucose (Table S1). Mannose, which recently underwent extensive study with regard to insulin resistance (Lee et al., 2016), was nominally associated with insulin resistance after controlling for BMI in our study ($p = 0.004$).

**Evolution of Obesity and Metabolome Clinical Profiles**

Given recent work suggesting that obese individuals who are metabolically healthy may remain at higher risk of negative health outcomes than are normal weight individuals who are metabolically healthy (Caleyachetty et al., 2017), we next asked whether the outlier groups were more likely to become obese over time. Focusing on the 1,458 individuals from TwinsUK who had weight measurements at all three time points, we found that those who had an mBMI that was higher than their BMI were marginally more likely to gain weight and convert to an obese phenotype (BMI > 30) over the 8–18 years of follow up. For example, 32.8% of those of normal weight but with an overweight or obese metabolome converted to being overweight or obese by time point 3 compared to 24.8% of those who were of normal weight and had a healthy metabolome ($p = 0.01$; Figure 4). However, this association was not strongly supported, and overall, the mBMI states of the individuals remained fairly stable with time and were a function of BMI changes (Figure 4). For example, 68% of the individuals who began the study with an obese metabolome ended the study with an obese metabolome. When an individuals’ weight increased and then decreased, their mBMI followed suit, and no single metabolite was significantly predictive of subsequent BMI changes. In summary, our results are consistent with a favorable long-term health benefit for the overweight and obese individuals with a healthy metabolome.

**Cardiovascular Disease Outcomes**

Obesity is considered a risk factor for cardiovascular disease and ischemic stroke (Rhee, 2018). In the TwinsUK study, 32 of 1,573 individuals reported having had a cardiovascular event (myocardial infarct, angina, or angioplasty) or stroke prior to baseline. We found significant differences between mBMI/BMI groups in their reported baseline cardiovascular events (Fisher’s exact $p = 0.01$). In particular, the mBMI << BMI outliers had no history of cardiovascular events, whereas the mBMI >> BMI outliers had a proportion of historical events that was similar to those of overweight and obese individuals (Figure 4C). Information about blood pressure medication use was also available for 379 individuals at baseline, and those with mBMI >> BMI had very high rates of use compared to mBMI << BMI (Fisher’s exact $p = 0.00003$; Figure 4C). The longitudinal nature of the TwinsUK study also allowed the collection of clinical endpoints in these unselected participants. The age of participants at the first visit ranged from 33 to 74 years old (median 51), and 42 to 88 years old (median 65) at the last visit. During the follow up (median 13 years), the study recorded 53 cardiovascular events (myocardial infarct, angina, or angioplasty) or strokes for 1,573 individuals. We calculated that our study had 80% power to identify effects with a hazard ratio of at least 1.5 for differences in cardiovascular event outcomes between the different mBMI/BMI groups. We found that participants with a healthy metabolome (normal BMI, overweight, or obese) had 2.6 events per hundred individuals. Individuals with an obese metabolic profile, mBMI, had 3.4 (normal/overweight BMI) and 4.4 events (in obese individuals) per hundred individuals. Separated analysis of the various endpoints confirmed the trends, more accentuated for cardiovascular than for diagnosis of stroke. We then performed a formal survival analysis for participants to have any cardiovascular event after the first time point, and we found those with healthier metabolomes to have fewer/later cardiac events ($p = 0.003$; Figure 4D).

**Correlations between Twins**

Because twin studies are important to analyze the heritability of traits, we reassessed the BMI model predictions and obesity status of 350 sets of twins where either both twins had normal BMI ($n = 244$), both twins were obese ($n = 67$), or one was obese and the other had normal BMI ($n = 39$). To keep the categories clear, individuals with BMIs between 25 and 30 (overweight) and their twins were excluded. As asserted by the model’s high specificity and sensitivity, the metabolite-based obesity predictions reflected the actual obesity status of the individuals. This was even the case when only one twin was obese: the obese twin was generally predicted by their metabolome to be obese, while the normal weight twin was not (Figure S1). The correlations between the metabolite-based obesity predictions were also substantially higher between the monozygotic twins than the dizygotic twins, as expected. Interestingly, we identified three sets of twins where both twins were predicted from the metabolome to be of normal weight, but both were obese, and eight sets of twins where the reverse was true. These outliers were thought to represent healthy obese and normal weight, metabolically unhealthy individuals described above.
Figure 2. Variables Associated with BMI and Predicted BMI from the Metabolome

(A) Correlation between ridge regression model prediction of BMI and actual BMI for all unrelated individuals of European ancestry in the TwinsUK and Health Nucleus dataset. The identification of outliers is defined below: the pink box shows individuals with a much lower predicted BMI (mBMI) than actual BMI, and the yellow box shows individuals with a much higher mBMI than actual BMI.

(B) Factors associated with being an mBMI outlier. Participants were split into five groups: those whose metabolome accurately predicted their BMI (residual after accounting for age, sex, and BMI between −0.5 and 0.5), whose BMIs were either normal (18.5–25), overweight (25–30), or obese (>30), and those whose metabolome predicted a substantially higher mBMI than the actual BMI (residual < −0.5) or a substantially lower mBMI than the actual BMI (residual > 0.5). All y axis values are scaled to a range from 0 to 1 to allow comparison across groups.

(legend continued on next page)
Known Genetics of Obesity

We first investigated the known genetic factors contributing to high BMI. We calculated polygenic risk scores for BMI using known associations from the considerable literature of obesity and BMI GWAS (genome-wide association study) (Locke et al., 2015). As previously reported, we found that polygenic risk score only explained 1.2%–2.2% of the variation in BMI at each of the three TwinsUK time points and in Health Nucleus for unrelated participants of European ancestry (Figure S4). We investigated whether unique individuals with the highest polygenic risk scores would have a significant perturbation of the metabolome and anthropomorphic, insulin resistance, and DEXA measurements (Figure 5). While the data did not support a strong role for polygenic risk, there were trends for higher polygenic risk scores to be associated with a higher android/gynoid ratio (p = 0.04), waist/hip ratio (p = 0.03), and triglycerides (p = 0.01). However, there was no statistical association between the polygenic score and mBMI (p = 0.07).

Studies of rare variants in obesity have identified melanocortin 4 receptor (MC4R) mutations as having effects large and clear enough to be appropriate for study in our dataset (Collet et al., 2017; Turcot et al., 2018). We therefore identified members of the study populations who were carrying rare (MAF < 0.01%) coding variants in MC4R. We identified eight such carriers in the subset of unrelated participants (Table 2). Each variant was observed in one unrelated individual, and six of the eight had already been annotated as causing obesity in clinical databases HGMD or ClinVar (Table 2). As a group, MC4R carriers had significantly higher BMI (p = 0.02) than did non-carriers as well as non-significant trends toward a higher diastolic blood pressure, insulin resistance, and percent body fat (Figure 5). However, it is known that not all rare variants are deleterious, and the metabolic impact could have been greater for the true subset of functional variants. The BMI data in the participants supported a pathogenic role for at least five of the variants (Met292fs, Arg236Cys, Ser180Pro, Ala175T, and Thr11Ala), but did not corroborate a role of Ile170V, which is defined in HGMD, ClinVar, and the literature as pathogenic (Clement et al., 2018; Collet et al., 2017; Landrum et al., 2018; Stenson et al., 2003). Importantly, of the five sets of twins who both carried the same MC4R variant, three sets included twins who were both overweight or obese. In the two cases where a carrier’s twin did not have the MC4R variant, their BMI was lower than their twin’s.

Figure 3. Body Composition Profiles from Dixon Magnetic Resonance Imaging for Four Outlier Individuals

(A) Correlation between ridge regression model prediction of BMI and actual BMI for all unrelated individuals of European ancestry in the TwinsUK and Heath Nucleus dataset. Outliers highlighted in (B) and (C) are marked with corresponding colors. All individuals highlighted are from the outlier mBMI >> BMI or mBMI << BMI categories shown in Figure 2.

(B) Body composition profiles (red, visceral adipose tissue; yellow, subcutaneous adipose tissue; cyan, muscle).

(C) Waist to hip cross-sections (hip, mid femoral head; waist, top of ASIS).
We observed an enrichment of MC4R variant carriers among obese individuals with low polygenic risk scores (Figure S4). Out of 37 participants who were obese with polygenic risk scores in the lowest quartile, 5.4% were MC4R variant carriers, while the carrier frequency was just 0.4% in those of normal weight.

We also searched the study population for rare variants associated with Mendelian lipodystrophy syndromes. Lipodystrophies are heterogeneous, genetic, or acquired disorders characterized by selective loss of body fat and associated metabolic complications such as diabetes mellitus, hypertriglyceridemia, and hepatic steatosis (Garg, 2011). We identified six individuals with rare heterozygous variants in four genes: ZMPSTE24, AGPAT2, LIPE, and BSCL2 (Table 2). The individuals with LIPE or BSCL2 variants were of normal weight but were in the mBMI >> BMI outlier category. The three individuals with ZMPSTE24 p.Leu362fs caused by a 1-bp insertion had normal to low BMI and mBMI. We also observed an unannotated 1-bp deletion at this site in one obese individual (Table 2; Figure S5). While these observations are interesting, there are no data in the literature to support a phenotypic role for these variants in carriers (heterozygotes).

**Genetics of the Metabolically Healthy Obese**

Individuals with an mBMI that was substantially lower than their actual BMI had a higher polygenic risk score for BMI than did other groups. In contrast, those whose mBMI was substantially higher than their actual BMI had low polygenic risk scores.
This result would support the notion that the polygenic risk score for BMI may capture an anthropomorphic phenotype (larger-framed individuals) rather than a unique association with obesity as a disease trait.

Last, we investigated whether obese individuals with different genetic backgrounds had different metabolomes from other obese individuals. We first searched for metabolites, BMI-associated or otherwise, that could distinguish individuals with different BMI polygenic risk scores or *MC4R* variant carriers. Linear regression showed no significant associations between any single metabolites and polygenic risk or *MC4R* carrier status in either the entire population or in only the obese individuals. This result implies that metabolites are unlikely to be intermediate phenotypes that explain the underlying genetics of obesity. To check for more specific signals beyond the compiled polygenic risk score, we also performed separate analyses of each of the 97 variants that are used to calculate the polygenic risk score. We found no evidence for any of these known GWAS variants to be more strongly associated with a metabolite than with BMI itself, though our power for discovery was limited given the very small effect sizes of most individual GWAS variants. In summary, although it is known that there is a strong genetic component to metabolite levels (Long et al., 2017), most of the metabolic perturbations that occur in the obese state are a response to obesity as opposed to shared genetic mechanisms.

**DISCUSSION**

The results of the present study highlight the profound disruption of the metabolome in obesity and identify a metabolome signature that serves to examine metabolic health without the limitations of anthropomorphic measurements or the cost, time, and equipment requirements of imaging technologies. Nearly one-third of the approximately 1,000 metabolites measured in the study were associated with BMI, and 49 were selected as a
| Gene       | Variant     | Protein Change | Study MAF | Global Gnomad MAF | Known Functional Annotation | Carrier BMI (mBMI) | Carrier Twin BMI (mBMI) | Non-carrier Twin BMI (mBMI) | Twin Zygosity |
|------------|-------------|----------------|-----------|-------------------|----------------------------|--------------------|------------------------|-----------------------------|----------------|
| **Obesity**|             |                |           |                   |                            |                    |                        |                             |                |
| MC4R       | chr18:60371541 G/A | p.Ser270Phe   | 0.04%     | 0.00%             | none                       | 25.7 (26.1)        | 24.8 (24.7)            | N/A                          | MZ              |
| MC4R       | chr18:60372307 G/A | p.Leu15Phe    | 0.04%     | 0.00%             | none                       | 23 (22.6)          | 22.6 (22.4)            | N/A                          | MZ              |
| MC4R       | chr18:60371474 CA/C | p.Met292fs    | 0.04%     | <0.003%          | (complete LOF)            | 32.8 (26)          | N/A                    | 28.8 (24.3)                | DZ              |
| MC4R       | chr18:60371644 G/A | p.Arg236Cys   | 0.04%     | 0.00%             | HGMD highC DM (not LOF)    | 34.5 (32.3)        | 30 (27.5)              | N/A                          | DZ              |
| MC4R       | chr18:60372319 T/C | p.Thr11Ala    | 0.04%     | <0.003%          | HGMD lowC DM (not LOF)     | 36 (31.7)          | N/A                    | N/A                          | N/A             |
| MC4R       | chr18:60371812 A/G | p.Ser180Pro   | 0.04%     | <0.003%          | ClinVar LP (partial LOF)   | 34.2 (30.2)        | 34.4 (33.5)            | N/A                          | DZ              |
| MC4R       | chr18:60371827 C/T | p.Ala175Thr   | 0.04%     | 0.02%            | ClinVar P HGMD highC DM (partial LOF) | 29 (25.6)  | 28.5 (24.4)            | N/A                          | MZ              |
| MC4R       | chr18:60371842 T/C | p.Ile170Val   | 0.04%     | 0.01%            | ClinVar P HGMD highC DM (partial LOF) | 22.6 (23.7) | N/A                    | 21.3 (24.7)                | DZ              |
| **Lipodystrophy** |      |                |           |                   |                            |                    |                        |                             |                |
| ZMPSTE24   | chr1:40290870 G/GT | p.Leu362fs    | 0.11%     | 0.03%             | ClinVar P                  | 18 (18.9)          | N/A                    | N/A                          | N/A             |
| ZMPSTE24   | chr1:40290870 G/GT | p.Leu362fs    | 0.11%     | 0.03%             | ClinVar P                  | 22 (20.3)          | N/A                    | N/A                          | N/A             |
| ZMPSTE24   | chr1:40290870 G/GT | p.Leu362fs    | 0.11%     | 0.03%             | ClinVar P                  | 22.4 (26.1)        | N/A                    | 22.6 (25.1)                | DZ              |
| ZMPSTE24   | chr1:40290870 G/GT | p.Leu362fs    | 0.04%     | <0.003%          | not annotated              | 30.7 (27.5)        | N/A                    | 24.9 (24.1)                | DZ              |
| AGPAT2     | chr9:13667387 G/C | p.Ala238Gly   | 0.04%     | 0.00%             | HGMD highC DM              | 20 (23.3)          | N/A                    | N/A                          | N/A             |
| LIPE       | chr19:42401821 CCCCGGCAGCC CCCTGTA/C | p.Val1068fs | 0.04%     | 0.07%            | ClinVar P                  | 23 (27.4)          | N/A                    | N/A                          | N/A             |
| BSCL2      | chr11:62692371 C/T | c.863+5G>A    | 0.04%     | <0.003%          | ClinVar P                  | 24 (29.9)          | N/A                    | N/A                          | N/A             |

MAF, minor allele frequency; HGMD highC DM, Human Gene Mutation Database high-confidence disease-causing mutation; lowC, low confidence; ClinVar LP, likely pathogenic; P, pathogenic; MZ, monozygotic; DZ, dizygotic. Each variant was only seen once in the unrelated participants of this study. See alignments in Figure S5.

*This deletion at the same site as a lipodystrophy insertion has not previously been annotated.

bFunctional annotation according to Collet et al. (2017), where LOF = loss of function.
strong signature for the study of the relationship between BMI, obesity, metabolic disease, and the genetics of BMI. Consistent with previous studies and earlier work in the TwinsUK cohort, branched-chain and aromatic amino acids, and metabolites involved in nucleotide metabolism, such as urate and pseudouridine, are strongly perturbed by obesity (Butte et al., 2015; Ho et al., 2016; Menni et al., 2017; Park et al., 2015). The underlying reason for the perturbation of branched-chain amino acid metabolism in obese individuals and those with insulin resistance is thought to be related to differences in the amino acid catabolism in adipose tissue (Newgard, 2012). The single metabolite with the most significant association with BMI was urate, as we previously reported (Menni et al., 2017). It is well known that uric acid increases with obesity, due to insulin resistance reducing the kidneys’ ability to eliminate uric acid, but previous work has not emphasized the power of urate to predict BMI (Butte et al., 2015; Facchini et al., 1991; Ho et al., 2016). We also found a strong signal for lipids to be associated with BMI, with an enrichment of associations found for glycerol lipids. These results are consistent with previous studies showing that sphingomyelins and diacylglycerols increase with BMI while lysophosphocholines decrease with BMI, with other various phosphatidylcholines having effects in both directions (Butte et al., 2015; Ho et al., 2016; Park et al., 2015). A number of BMI-associated metabolites (12 of the 49-metabolite signature) were associated with insulin resistance after controlling for BMI. As previously observed (Caleyachetty et al., 2017; Oberbach et al., 2011; Reinehr et al., 2015; Wahl et al., 2015), the metabolome abnormalities associated with high BMI corrected with loss of weight. However, our study found that metabolite levels did not provide predictive power for future weight changes. Overall, the metabolome perturbations appear as a consequence of changes in weight as opposed to being a contributing factor.

While BMI correlates well and to a large extent with individual health outcomes, it does not have the sensitivity to identify outliers, some of which carry unique health consequences. These limitations to BMI are recognized in the literature (Neeland et al., 2018). Here, the metabolome signature identified individuals whose predicted mBMI was either substantially lower or higher than their actual BMI, i.e., individuals with lesser or greater metabolic consequences of obesity, using a technology that is amenable to large-scale implementation. These individuals include the metabolically healthy obese, but we also emphasize the importance of the metabolome anomalies in identifying unhealthy individuals with a normal BMI. These profiles were generally stable over the prolonged follow up. An abnormal metabolome was associated in the present study with an approximately 5-fold increase in baseline cardiovascular events and additional 2-fold increase in cardiovascular events during follow up when comparing individuals who were matched for BMI but who had opposing metabolome signatures. Thus, while our findings are in line with the known relationships between metabolically healthy obese status and health-related traits like metabolic syndrome and body fat (Brochu et al., 2001; Caleyachetty et al., 2017; Karelis et al., 2005), we extend this relationship to the broader category of metabolically healthy and unhealthy individuals on the basis of the disparity between mBMI and BMI. For example, we observed differences in waist/hip ratio, percent visceral fat, and blood pressure between mBMI/BMI outliers despite having the same BMI distribution. The fact that the metabolically healthy obese have a high BMI polygenic risk score also supports the concept that some of the genetic studies may capture anthropomorphic associations—body size—rather than obesity sensu stricto. Overall, the health consequences observed across the various mBMI groups indicate that there is a durable benefit of maintaining a healthy metabolome signature and point to an ongoing risk for the individuals that have an unhealthy metabolome despite stability of BMI.

In line with the observation that a richer set of biomarkers is more accurate than a narrower panel of single biomarkers, we observed that 650 metabolites could explain ~50% and a 49-metabolite signature of the best markers could explain 43% of variance in BMI. In contrast, a conventional model that included age, sex, HDL, LDL, total cholesterol, and triglycerides could explain 31%, while the best single metabolic marker (urate) could explain 16% of the variance in BMI. The message that emerges from these types of observations—and that will become central to the implementation of machine and deep learning in medicine—is that there is a substantial loss of signal associated with the quest for a single biomarker. The medical system would, however, need to validate and establish the health economics of rich data biomarkers to foster adoption in clinical diagnostic routine.

In contrast with metabolomics analyses, the present study does not support a strong association between metabolome changes and the genetics of BMI defined by a 97-variant polygenic risk score (Locke et al., 2015). This may be explained by the fact that known BMI GWAS loci explain only a small fraction (~3%) of BMI heritability (Locke et al., 2015). Despite this overall lack of explanatory power, there was a clear signal for individuals with higher polygenic risk scores to have greater rates of obesity. Because the genetic risk score does not include rare variants, we also identified individuals who carried rare functional variants in the known obesity gene MC4R, which is the single best example of a gene where rare coding variants have a large effect on obesity (Turcott et al., 2018). The carriers of these variants were often obese individuals, but their metabolome was not categorically different from that of other obese individuals. The lack of metabolome differences for carriers of variants in this gene is not surprising given that MC4R variants cause obesity by increasing appetite. However, we did find that obese carriers of MC4R variants often had low polygenic risk scores for obesity; out of 31 participants who were obese with polygenic risk scores in the lowest quartile, 5.4% were MC4R variant carriers, while the carrier frequency was just 0.4% in those of normal weight. Thus, our study shows the interest of sequencing obese individuals with low polygenic risk scores because of the apparent enrichment for monogenic contributions. As we completed this study, a large consortium provided additional detail on the role of variants in pathways that implicate energy intake and expenditure in obesity (Turcott et al., 2018). Future studies should also explore the role of rare functional variants in lipodystrophy genes on the metabolic traits in the general population.

In summary, the present study highlights the health risks of the perturbed metabolome. The study also indicates that the genetics of BMI are separate from metabolic health and serves to prioritize a subset of individuals for genetic analysis. The
assessment of the metabolome and genome of BMI lays groundwork for future studies of the heterogeneity of obesity and treatment of its endophenotypes. Specifically, the methodology used here can be applied to build similar models for insulin resistance, fat distribution, or any other number of clinical traits, and the mBMI metabolome signature can act as a biomarker of response to the new therapeutics that target patients with MC4R mutations (Kühnen et al., 2016). In the future, metabolic profiling could help select patients for clinical trials beyond genetic sequencing, thus expanding drug utility (Yanovski and Yanovski, 2018).

Limitations of Study
While the uniquely rich metabolomic and phenotypic data in this study permitted a thorough investigation of obesity-related health, there were nonetheless limitations. We chose to focus this study on BMI, the most widely used measurement of obesity. However, future studies building models for other traits of metabolic health, for example diabetes or visceral fat, may be of greater utility. Our study also had limited longitudinal information on medication use, which precluded an analysis of how drug prescription influenced mBMI/BMI categories and vice versa. Additionally, the association we observed between mBMI/BMI categories and longitudinal cardiovascular outcomes requires confirmation in a replication cohort.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHOD DETAILS**
  - Phenotyping
  - Metabolite Profiling
  - Genome Sequencing and Analysis
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND SOFTWARE AVAILABILITY**

SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and two tables and can be found with this article online at https://doi.org/10.1016/j.cmet.2018.09.022.

ACKNOWLEDGMENTS
We thank E. Muse for valuable comments. We acknowledge N. Schenker-Ahmed, L. Huang, M. Tyagi, and P. Sheth for aiding with data collection. TwinsUK receives funding from the Wellcome Trust, European Community’s Seventh Framework Programme (FP7/2007-2013, 277849, 201413, and 259749), the National Institute for Health Research (NIHR) Clinical Research Facility at Guy’s and St Thomas’ NHS Foundation Trust, and NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. A.T. is supported by the Qualcomm Foundation and the NIH Center for Translational Science Award (CTSA, grant number UL1TR002550).

AUTHOR CONTRIBUTIONS
A.T. and E.T.C. conceived of the experiment(s); E.T.C. conducted the experiment(s); L.G. supported metabolome analyses and interpretation; and E.T.C., J.C.V., and A.T. analyzed the results. C.T.C. and B.T. provided detailed insight into metabolic diseases; C.L.S., N.S., L.H., E.F.K., and L.A.N. aided with data collection and interpretation; and T.D.S. is responsible for the TwinsUK study. All authors reviewed the manuscript.

DECLARATION OF INTERESTS
E.T.C., C.L.S., N.S., L.H., L.A.N., E.F.K., C.T.C., and J.C.V. are currently or recently employed at Human Longevity, Inc. L.G. was recently an employee of Metabolome, Inc. A.T., B.T., and T.D.S. declare no conflict of interest.

REFERENCES
Abraham, S.B., Rubino, D., Sinai, N., Ramsey, S., and Nieman, L.K. (2013). Cortisol, obesity, and the metabolic syndrome: a cross-sectional study of obese subjects and review of the literature. Obesity (Silver Spring) 21, E105–E117.

Björntorp, P., and Rosmond, R. (2000). Obesity and cortisol. Nutrition 16, 924–936.

Brochu, M., Tchernof, A., Dionne, I.J., Sites, C.K., Eltabbakh, G.H., Sims, E.A., and Poeliman, E.T. (2001). What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J. Clin. Endocrinol. Metab. 86, 1020–1025.

Butte, N.F., Liu, Y., Zakeri, I.F., Mohney, R.P., Mehta, N., Voruganti, V.S., Göring, H., Cole, S.A., and Comuzzie, A.G. (2015). Global metabolomic profiling targeting childhood obesity in the Hispanic population. Am. J. Clin. Nutr. 102, 256–267.

Caleyachetty, R., Thomas, G.N., Touli, K.A., Mohammed, N., Gokhale, K.M., Balachandran, K., and Niranarukamrut, K. (2017). Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J. Am. Coll. Cardiol. 70, 1429–1437.

Chen, H.H., Tseng, Y.J., Wang, S.Y., Tsai, Y.S., Chang, C.S., Kuo, T.C., Yao, W.J., Shieh, C.C., Wu, C.H., and Kuo, P.H. (2015). The metabolome profiling and pathway analysis in metabolic healthy and abnormal obesity. Int. J. Obes. 39, 1241–1248.

Clément, K., Biebemann, H., Farooqi, I.S., Van der Ploeg, L., Wolters, B., Poitou, C., Puder, L., Fiedorek, F., Gottesdiener, K., Kleinau, G., et al. (2018). MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat. Med. 24, 551–555.

Cohen, I.V., Cirulli, E.T., Mitchell, M.W., Jonsson, T.J., Yu, J., Shah, N., Spector, T.D., Guo, L., Venter, J.C., and Teintl, A. (2018). Acetaminophen (paracetamol) use modifies the sulfation of sex hormones. EBioMedicine 28, 316–323.

Collet, T.H., Dubern, B., Mokrosinski, J., Connors, H., Keogh, J.M., Mendes de Oliveira, E., Henning, E., Poitou-Bernert, C., Oppert, J.M., Tounian, P., et al. (2017). Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol. Med. 23, 1321–1329.

Faccini, F., Chen, Y.D., Hollenbeck, C.B., and Reaven, G.M. (1991). Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266, 3008–3011.

Garg, A. (2011). Clinical review: lipodystrophies: genetic and acquired body fat disorders. J. Clin. Endocrinol. Metab. 96, 3313–3325.

Hales, C.M., Carroll, M.D., Fryar, C.D., and Ogden, C.L. (2017). Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief, 1–8.

Ho, J.E., Larson, M.G.M., Ghorbani, A., Cheng, S., Chen, M.-H., Keyes, M., Rhee, E.P.E.P., Clish, C.B., Vasan, R.S.R., Gerszten, R.E., and Wang, T.J. (2016). Metabolomic profiles of body mass index in the Framingham Heart Study reveal distinct cardiometabolic phenotypes. PLoS One 11, e0148361.
Iglesias Moli, A.E., Penas Steinhardt, A., López, A.P., González, C.D., Vilarinho, J., Frechetel, G.D., and Cerrone, G.E. (2017). Metabolically healthy obese individuals present similar chronic inflammation level but less insulin-resistance than obese individuals with metabolic syndrome. PLoS One 12, e0190528.

Incollingo Rodriguez, A.C., Epel, E.S., White, M.L., Staden, E.C., Seckl, J.R., and Tomiyama, A.J. (2015). Hypothalamic-pituitary-adrenal axis dysregulation and cortisol activity in obesity: a systematic review. Psychoneuroendocrinology 62, 301–318.

Karelis, A.D., Faraj, M., Bastard, J.P., St-Pierre, D.H., Brochu, M., Prud’homme, D., and Rabasa-Lhoret, R. (2005). The metabolically healthy but obese individual presents a favorable inflammation profile. J. Clin. Endocrinol. Metab. 90, 4145–4150.

Kühnen, P., Clément, K., Wiegand, S., Blankenstein, O., Gottesdiener, K., Martini, L.L., Mai, K., Blume-Peytavi, U., Grüters, A., and Krude, H. (2016). Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N. Engl. J. Med. 375, 240–246.

Landrum, M.J., Lee, J.M., Benson, M., Brown, G.R., Chao, C., Chitipiralla, S., Small, K.S., Mangino, M., Messier, H., et al. (2017). Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. Nat. Genet. 50, D1062–D1067.

Lee, S., Zhang, K., Kilicarslan, M., Piebing, B.D., Bjørnson, E., Hallström, B.M., Groen, A.K., Ferrarini, E., Laaksö, M., Snyder, M., et al. (2016). Integrated network analysis reveals an association between plasma mannose levels and insulin resistance. Cell Metab. 24, 172–184.

Lippert, C., Listgarten, J., Liu, Y., Kadie, C.M., Davidson, R.I., and Heckerman, D. (2011). FaST linear mixed models for genome-wide association studies. Nat. Methods 8, 833–835.

Locke, A.E., Kahali, B., Berndt, S.I., Justice, A.E., Pers, T.H., Day, F.R., Powell, C., Vedantam, S., Buchkovich, M.L., Yang, J., et al.; LifeLines Cohort Study; ADIPOGen Consortium; AGEN-BMI Working Group; CARDIOGRAMplusC4D Consortium; CKDGen Consortium; GLGC; ICBP; MAGIC Investigators; MuTHER Consortium; MiGen Consortium; PAGE Consortium; ReproGen Consortium; GENIE Consortium: International Endogene Consortium (2015). Genetic studies of body mass index yield new insights for obesity biology. Nature 518, 197–206.

Long, T., Hicks, M., Yu, H.-C., Biggs, W.H., Kirschner, E.F., Menni, C., Zierer, J., Small, K.S., Mangino, M., Messier, H., et al. (2017). Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. Nat. Genet. 49, 568–578.

Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., and Turner, R.C. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 422–419.

Menni, C., Migaud, M., Kastenmüller, G., Pallister, T., Zierer, J., Peters, A., Mohney, R.P., Spector, T.D., Bagnardi, V., Gieger, C., et al. (2017). Metabolomic profiling of long-term weight change: role of oxidative stress and urate levels in weight gain. Obesity (Silver Spring) 25, 1618–1624.

Moayyeri, A., Hammond, C.J., Hart, D.J., and Spector, T.D. (2013). The UK Adult Twin Registry (TwinUK Resource). Twin Res. Hum. Genet. 16, 144–149.

Neeleman, I.J., Poirier, P., and Després, J.-P. (2018). Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation 137, 1391–1406.

Newbard, C.B. (2012). Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 15, 606–614.

Oberbach, A., Blüher, M., Wirth, H., Till, H., Kovacs, P., Küllnick, Y., Schlichting, N., Tomm, J.M., Rolle-Kampczyk, U., Murugaiyan, J., et al. (2011). Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. J. Proteome Res. 10, 4769–4788.

Park, S., Sadanala, K.C., and Kim, E.-K. (2015). A metabolomic approach to understanding the metabolic link between obesity and diabetes. Mol. Cells 38, 587–596.

Perkins, B.A., Caskey, C.T., Brar, P., Dec, E., Karow, D., Kahn, A., Hou, C., Shah, N., Boeijing, D., Coughlin, E., et al. (2017). Precision medicine screening using whole genome sequencing and advanced imaging to identify disease risk in adults. bioRxiv. https://doi.org/10.1101/133538.

Pieing, B.D., Zhou, W., Contrepois, K., Röst, H., Gu Urban, G.J., Mishra, T., Hanson, B.M., Bautista, E.J., Leopold, S., Yeh, C.Y., et al. (2018). Integrative personal omics profiles during periods of weight gain and loss. Cell Syst. 6, 157–170.e8.

Praveen, E.P., Sahoo, J.P., Kulshreshtha, B., Khurana, M.L., Gupta, N., Dwivedi, S.N., Kumar, G., and Ammini, A.C. (2011). Morning cortisol is lower in obese individuals with normal glucose tolerance. Diabetes Metab. Syndr. Obes. 4, 347–352.

Reinehr, T., Wolters, B., Knoop, C., Lass, N., Hellmuth, C., Harder, U., Peissner, W., Wahl, S., Grallert, H., Adansami, J., et al. (2015). Changes in the serum metabolite profile in obese children with weight loss. Eur. J. Nutr. 54, 173–181.

Rhee, E.J. (2018). Being metabolically healthy, the most responsible factor for vascular health. Diabetes Metab. J. 42, 19–25.

Stenson, P.D., Ball, E.V., Mort, M., Phillips, A.D., Shiel, J.A., Thomas, N.S.T., Abeyesinghe, S., Krawczak, M., and Cooper, D.N. (2003). Human Gene Mutation Database (HGMD): 2003 update. Hum. Mutat. 21, 577–581.

Talenti, A., Pierce, L.C.T., Biggs, W.H., di Iulio, J., Wong, E.H.M., Fabani, M.M., Kirschner, E.F., Moustaﬁ a, A., Shah, N., Xie, C., et al. (2016). Deep sequencing of 10,000 human genomes. Proc. Natl. Acad. Sci. USA 113, 11901–11906.

Turcot, V., Lu, Y., Highland, H.M., Schumarr, C., Justice, A.E., Fine, R.S., Bradford, J.P., Esko, T., Giri, A., Graft, M., et al.; CHD Exome+ Consortium; EPIC-CVD Consortium; ExomeBP Consortium; Global Lipids Genetic Consortium; GoT2D Genes Consortium; EPIC InterAct Consortium; INTERVAL Study; ReproGen Consortium; T2D-Genes Consortium; MAGIC Investigators; Understanding Society Scientific Group (2018). Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nat. Genet. 50, 26–41.

Wahl, S., Vogt, S., Stuckler, F., Krumsiek, J., Bartel, J., Kacprzowski, T., Schramm, K., Carstensen, M., Rathmann, W., Roden, M., et al. (2015). Multi-omic signature of body weight change: results from a population-based cohort study. BMC Med. 13, 48.

Walker, B.R., Soderberg, S., Lindahl, B., and Olsston, T. (2000). Independent effects of obesity and cortisol in predicting cardiovascular risk factors in men and women. J. Intern. Med. 247, 198–204.

Whitlock, G., Lewington, S., Sherkinger, P., Clarke, R., Emberson, J., Halsey, J., O’Callaghan, M., Qizilbash, N., Collins, R., and Peto, R.; Prospective Studies Collaboration (2008). Prospective studies collaborative analyses of 57 prospective studies. Lancet 371, 1083–1096.

WHO (2018). Obesity and overweight. http://www.who.int/news-room/factsheets/detail/obesity-and-overweight.

Wilkof, W.R., Anfora, A.T., Liu, J., Schultz, P.G., Lesley, S.A., Peters, E.C., and Szudades, G. (2009). Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA 106, 3698–3703.

Wirix, A.J.G., Finken, M.J.J., von Rosenstiel-Jadoul, I.A., Heijboer, A.C., Nauta, J., Groothoff, J.W., Chinapaw, M.J.J., and Kist-van Hothe, J.E. (2017). Is there an association between cortisol and hypertension in overweight or obese children? J. Clin. Res. Pediatr. Endocrinol. 9, 344–349.

Yanovski, S.Z., and Yanovski, J.A. (2018). Toward precision approaches for the prevention and treatment of obesity. JAMA 319, 223–224.
# STAR METHODS

## KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Deposited Data      |        |            |
| gnomad, Genome Aggregation Database | http://gnomad.broadinstitute.org/ | RRID: SCR_014964 |
| ClinVar             | https://www.ncbi.nlm.nih.gov/cclinvar/ | RRID: SCR_006169 |
| HGMD, Human Gene Mutation Database | http://www.hgmd.cf.ac.uk/ac/index.php | RRID: SCR_001888 |
| Study data deposited into Mendeley Data | This paper; https://data.mendeley.com/ | https://doi.org/10.17632/kpjsnwd2mc.1 |
| Study data and scripts deposited into GitHub | This paper; https://github.com | https://github.com/humanlongevity/mbmi |

## CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Elizabeth Cirulli (liz.cirulli@gmail.com).

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

The study included 1,969 largely European ancestry twins enrolled in the TwinsUK registry, a British national register of adult twins (Moayyeri et al., 2013). We previously reported a detailed study of the genetic variants influencing the human metabolome in this cohort (Long et al., 2017). Serum samples were collected at three visits, 8-18 (median 13) years apart. The cohort is mainly composed of females (96.7%), and the sample set we used included 388 monozygotic twin pairs, 519 dizygotic twin pairs, and 155 unrelated individuals. The age of participants at the first time point ranged from 33 to 74 years old (median 51); 36 to 81 years old (median 59) at the second time point; and 42 to 88 years old (median 65) at the third time point. The BMI values measured at each metabolome time point were taken within two years of the blood draw date. At baseline, 36.3% of the female participants and 53.8% of the male participants were overweight, and 16.9% of the females and 10.8% of the males were obese. The twins study was approved by St. Thomas’ Hospital Research Ethics Committee, and all participants provided informed written consent. BMI data were available for 1743 participants within two years of the time point for metabolome time point 1, 1834 for within two years of time point 2, and 1777 for up to 2 years before time point 3 or 4 years after this time point; 1,458 individuals had all three datapoints.

For independent validation and studies of phenotypes correlated with metabolic BMI outliers, we enrolled 427 unselected adults more than 18 years old who were able to come to the Health Nucleus in La Jolla, CA for a clinical research protocol (Perkins et al., 2017). Participants ranged in age from 18-89 years old (median 53), were 32.9% female, and had BMI data measured at one time point: 16.7% of the female participants and 47.5% of the male participants were overweight, and 7.2% of the females and 23.7% of the males were obese.

## METHOD DETAILS

### Phenotyping

Individuals in the TwinsUK cohort and Health Nucleus both underwent dual-energy X-ray absorptiometry (DEXA) imaging. The data from these scans were used to calculate android/gynoid ratio, percent body fat, visceral fat, and subcutaneous fat. DEXA is very accurate in the measurement abdominal visceral adipose tissue (VAT). High levels of VAT are associated with atherogenic dyslipidemia, hyperinsulinemia, and glucose intolerance (Neeland et al., 2018). TwinsUK cohort participants were additionally measured for circumference at the waist and hip using a measuring tape to calculate the waist/hip ratio. TwinsUK participants self-reported information about whether they were taking high blood pressure medication at their first visit and about cardiovascular events and their timing via a survey at the final visit. For a selected number of Health Nucleus participants, images of fat and water (imaging of muscle) were available from symmetrical chemical shift Magnetic Resonance Imaging (MRI) via the Dixon method. Quantitative insulin...
resistance (homeostatic model assessment, HOMA) was calculated as fasting insulin x fasting glucose / 405, and being insulin resistant was defined by HOMA score $\geq 3$ (http://gihep.com/calculators/other/homa/) (Matthews et al., 1985).

**Metabolite Profiling**

The non-targeted metabolomics analysis of 901 metabolites in the TwinsUK cohort and 1,007 metabolites in the Health Nucleus cohort was performed at Metabolon (Durham, North Carolina, USA) on a platform consisting of four independent ultra high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) methods. The detailed descriptions of the platform can be found in our previous publications (Cohen et al., 2018; Long et al., 2017). For the TwinsUK cohort, blood serum after fasting was used for analysis, and the resulting raw values were transformed to z scores using the mean and standard deviation. For the Health Nucleus cohort, blood plasma after fasting was used for analysis, and values from multiple experimental batches were normalized into Z-scores based on a reference cohort of either 42 (n = 457) or 300 (n = 176) self-reported healthy individuals run with each batch. The 42 and 300-normalized batches were converted to the same scale using linear transformation based on the values obtained from 7 runs that included both the 42 and 300 controls. Samples with metabolite measurements that were below the detection threshold were imputed as the minimum value for that metabolite.

**Genome Sequencing and Analysis**

As previously described (Telenti et al., 2016), DNA samples were sequenced on an Illumina HiSeqX sequencer utilizing a 150 base paired-end single index read format. Reads were mapped to the human reference sequence build HG38. Variants were called using ISIS Analysis Software (v. 2.5.26.13; Illumina). A linear mixed model was applied to account for family structure in the cohort while testing for associations between genetic variants and the different phenotypes: BMI; BMI prediction model values and residuals after accounting for BMI, age, sex; and levels of the 49 BMI-associated metabolites. A genetic similarity matrix (GSM) was constructed from 301,556 variants that represented a random 20% of all common (MAF > 5%) variants genome-wide after linkage-disequilibrium (LD) pruning ($r^2$ less than 0.6, window size 200 kb) and was used to model the random effect in the linear mixed model via a “leave-out-one-chromosome” method for each tested variant. Each of 97 known BMI-associated variants was tested independently using customized Python scripts wrapping the FaST-LMM package (FaST LMM, RRID: SCR_015506) (Lippert et al., 2011; Locke et al., 2015). Principal component axes were calculated to check ethnicity using plink, and the first principal component for those of European ancestry was used as a covariate in analyses of unrelated individuals in R described below. Polygenic risk scores were calculated using genotypes for 97 variants whose associations and betas had been published previously (Locke et al., 2015). Rare variants in the gene MC4R were defined as coding and splice variants with MAF < 0.1%. Rare lipodystrophy variants were defined as those achieving a pathogenic or likely pathogenic categorization in ClinVar (ClinVar, RRID: SCR_006169) or HGMD (HGMD, RRID: SCR_001888). Allele frequencies were calculated in our set of samples and also retrieved from gnomad (Genome Aggregation Database, RRID: SCR_014964).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

R (R Project for Statistical Computing, RRID: SCR_001905) was used for the analysis and data manipulation. Bonferroni correction was used for all analyses, and most statistical analyses were restricted to unrelated individuals of European ancestry, in accordance with field standards for ensuring that ancestry differences do not cause bias or skew in the results. For each quantitative analysis of BMI or other traits, the subset of BMI values or other outcome variables used were rank-ordered and forced to a normal distribution. Analyses comparing metabolites to BMI were performed in R using the lm function, and age, sex, and the first genetic principal component were included as covariates. The obesity prediction model was built using ridge regression (alpha = 0) with glmnet in R. The residuals used to separate participants into the five categories shown in Figure 2 were calculated using age, sex, and initial BMI. Heatmaps were generated in R using the pheatmap package. Survival analysis was performed using coxph in R with age at first visit included as a covariate. Power calculation was performed using the power.stratify command in the powerSurvEpi package in R.

**DATA AND SOFTWARE AVAILABILITY**

The R analysis scripts and data files used are available at https://github.com/humanlongevity/mbmi. Data files have been deposited to Mendeley Data and are available at https://doi.org/10.17632/kpjsnwd2mc.1.
Supplemental Information

Profound Perturbation of the Metabolome
in Obesity Is Associated with Health Risk

Elizabeth T. Cirulli, Lining Guo, Christine Leon Swisher, Naisha Shah, Lei Huang, Lori A. Napier, Ewen F. Kirkness, Tim D. Spector, C. Thomas Caskey, Bernard Thorens, J. Craig Venter, and Amalio Telenti
Profound perturbation of the metabolome in obesity associates with health risk

Elizabeth T. Cirulli¹*, Lining Guo², Christine Leon Swisher¹, Naisha Shah¹, Lei Huang¹, Lori A. Napier¹, Ewen F. Kirkness¹, Tim D. Spector³, C. Thomas Caskey⁴, Bernard Thorens⁵, J. Craig Venter⁶, and Amalio Telenti⁷*

Supplementary Figures

Figure S1. Obesity prediction, Related to Figure 2.
Figure S2. Factors associated with having a metabolic BMI different from actual BMI, Related to Figure 2.
Figure S3. Metabolite levels and their relationship to mBMI/BMI category, Related to Table 1.
Figure S4. Genetics of BMI, Related to Table 2.
Figure S5. Alignments at ZMPSTE24 p.Leu362fs, Related to Table 2.
**Figure S1. Obesity prediction, Related to Figure 2.** Shown is the receiver operating characteristic (ROC) curve for the BMI prediction model to distinguish A) obese (BMI $\geq 30$) from normal weight (BMI 18.5-25) and B) overweight or obese (BMI $\geq 25$) from normal weight (BMI 18.5-25). The train (black) AUC were 0.918 (A) and 0.795 (B), and the test (blue) AUC were 0.926 (A) and 0.804 (B). The test specificities were 89.7% (A) and 68.7% (B), with 80.2% (A) and 80.7% (B) sensitivity. C) and D) show the obesity prediction and actual obesity status for 350 sets of twins. Shown is the BMI model prediction for each individual plotted against their twin’s prediction. The heavier twin is always on the X axis, and twins are color-coded to indicate their actual BMI status. C) shows the 144 monozygotic twins ($r^2=0.64$), and D) shows the 206 dizygotic twins ($r^2=0.33$). When both twins were obese, they both generally had high BMI model predictions, and when both twins were normal weight, they both generally had low BMI predictions. When only one twin was obese (green, X axis) and the other was normal weight (green, Y axis), the obese twin almost always had the higher BMI.
prediction.
Figure S2. Factors associated with having a metabolic BMI different from actual BMI, Related to Figure 2. A) Participants were split into 9 groups: normal weight, metabolically healthy (gray; BMI 18.5-25, BMI prediction below overweight cutoff from Figure S2 B); overweight, metabolically overweight (orange; BMI 25-30, BMI prediction above overweight cutoff but below obese cutoff from Figure S2 A); obese, metabolically obese (red; BMI >=30, BMI prediction above obese cutoff from Figure S2 A); obese, metabolically healthy (pink 1; BMI >=30, BMI prediction below overweight cutoff); obese, metabolically overweight (pink 2; BMI >=30, BMI prediction below obese cutoff); overweight, metabolically healthy (pink 3; BMI 25-30, BMI prediction below overweight cutoff); normal, metabolically obese (yellow 1; BMI 18.5-25, BMI prediction above obese cutoff); normal, metabolically overweight (yellow 2; BMI 18.5-25, BMI prediction above overweight cutoff); and overweight, metabolically obese (yellow 3; BMI 25-30, BMI prediction above obese cutoff). All y-axis values are scaled to a range from 0-1 to allow comparison across groups. The same process is used in B) to show imaging (DEXA or MRI) values associated with metabolic BMI outliers. BMI = body mass index; IR = insulin resistance; WH = waist/hip ratio; SYSBP = systolic blood pressure; DIABP = diastolic blood pressure; PG = polygenic risk score; AG = android/gynoid ratio; PFAT = percent fat; VAT = visceral fat; SAT = subcutaneous fat.
Figure S3. Metabolite levels and their relationship to mBMI/BMI category, Related to Table 1. Cortisone and asparagine show no statistically significant difference between the mBMI>>BMI and mBMI<<BMI groups, while leucine and urate (representative metabolites) do show significant differences.
Figure S4. Genetics of BMI, Related to Table 2. A) Mean polygenic risk score at each BMI as a function of age for timepoints 1, 2 and 3 in TwinsUK in red, green and blue, respectively. Note that the association of higher polygenic risk scores with higher BMIs appears stronger at earlier visits, i.e., younger ages. B) Shown is the carrier frequency of individuals with rare (MAF<0.001%) coding variants in MC4R broken down by obesity status and having a low (first quartile) polygenic risk score (PG). We identified 8 such carriers in the subset of unrelated participants, with an enrichment in participants who were obese despite a low polygenic risk score. Out of 37 participants who were obese with polygenic risk scores in the lowest quartile, 5.4% were MC4R variant carriers, while the carrier frequency was just 0.4% in those of normal weight. C) Of four obese MC4R variant carriers, two had a dizygotic twin who was also a carrier of the variant. In both cases, twins were obese despite having polygenic risk scores in the bottom quartile. Both sets of twins were predicted to be obese from their metabolome. Three of the four unrelated obese carriers of MC4R variants were also predicted to be obese from their metabolomes. Here, the polygenic risk scores of the twin pairs in the TwinsUK cohort are shown, broken down by whether both twins were obese (BMI>30) or normal weight (BMI 18.5-25) and predicted by the metabolome to be obese or normal weight. Obese twin pairs that carry MC4R variants are shown in red.
Figure S5. Alignments at ZMPSTE24 p.Leu362fs, Related to Table 2. A) Alignments of the T insertion in a carrier; B) alignments of the T deletion. The insertion is annotated as causal for recessive mandibuloacral dysplasia with type B lipodystrophy, and the deletion has not been previously annotated.